Silva Arslanian, ADA 2022: Dulaglutide for type 2 diabetes in youth, the AWARDS-PEDS study
The AWARDS-PEDS study assessed dulaglutide, a once-weekly subcutaneous injection of GLP-1 receptor agonist, in youth with type 2 diabetes and the key findings and implications are discussed by Dr Silva Arslanian (University of Pittsburgh, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA). The findings of this study come at a vital time, with type 2 diabetes at high levels amongst the youth, however, there are currently limited treatment options despite being a growing and progressive condition.Â
The abstract entitled ‘Dulaglutide in Youth with Type 2 Diabetes (T2D)—Results of the AWARD-PEDS Randomized, Placebo-Controlled Trial‘ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
Questions:Â
- What did the AWARD-PEDS study investigate? (0:21)
- What were the key findings for dulaglutide from AWARD-PEDS? (1:13)
- How can these findings support physicians in providing optimal support for young people with type 2 diabetes? (2:21)
Disclosures: Silva Arslanian is a consultant for and has received grant/research support from Novo Nordisk and Eli Lilly. Silva Arslanian is on the advisory board for the Data Monitoring Committee at AstraZeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
